Afghanistan
Tuberculosis profile
| High TB burden |
Population  2013 31 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 13 (8.4–16) 42 (27–53)
Mortality (HIV+TB only) 0.082 (0.065–0.1) 0.27 (0.21–0.33)
Prevalence  (includes HIV+TB) 100 (54–170) 340 (178–554)
Incidence  (includes HIV+TB) 58 (51–65) 189 (167–212)
Incidence (HIV+TB only) 0.2 (0.17–0.22) 0.64 (0.57–0.72)
Case detection, all forms (%) 53 (47–60)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 3.7 (2.5–4.9) 20 (13–27)
MDR-TB cases among notified pulmonary
TB cases
820 (560–1 100) 460 (300–610)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 14 277   1 154
Pulmonary, clinically diagnosed 8 020    
Extrapulmonary 7 056    
       
Total new and relapse 30 507    
Previously treated, excluding relapses 1 115    
Total cases notified 31 622    
Among 30 507 new and relapse cases:
3 454 (11%) cases aged under 15 years; male:female ratio: 0.7
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 7 (<1%) 38 (2%) 45
Laboratory-confirmed RR-/MDR-TB cases     73
Patients started on MDR-TB treatment     49
TB/HIV 2013 Number (%)
TB patients with known HIV status 8 247 (26)
HIV-positive TB patients 9 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB 100  
HIV-positive people provided with IPT 12  
Treatment success rate (%)
New and relapse cases registered in 2012 88
Previously treated cases, excluding relapse, registered in 2012 65
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 67
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 2.2
Culture (per 5 million population) 0.5
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 9.5
% Funded domestically 8%
% Funded internationally 57%
% Unfunded 35%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-08-01 Data: www.who.int/tb/data